Conditional Cell Reprogramming and Air-Liquid Interface Modeling Life Cycle of Oncogenic Viruses (HPV and EBV) in Epithelial Cells and Virus-Associated Human Carcinomas
- PMID: 37376685
- PMCID: PMC10302659
- DOI: 10.3390/v15061388
Conditional Cell Reprogramming and Air-Liquid Interface Modeling Life Cycle of Oncogenic Viruses (HPV and EBV) in Epithelial Cells and Virus-Associated Human Carcinomas
Abstract
Several oncogenic viruses are associated with approximately 20% of human cancers. Experimental models are crucial for studying the pathogenicity and biological aspects of oncogenic viruses and their potential mechanisms in tumorigenesis. Current cell models have considerable limitations such as: their low yield, genetic and epigenetic modification, and reduction in tumor heterogeneity during long propagation. Cancer cell lines are limited and not appropriate for studying the viral life cycle, for example, natural viral life cycles of HPV and EBV, and their persistence and latency in epithelial cells are poorly understood, since these processes are highly related to epithelial differentiation. Therefore, there is an urgent need of reliable human physiological cell models to study viral life cycle and cancer initiation. Conditional cell reprogramming (CCR) is a rapid and robust cell culture system, where the cells can be established from minimally invasive or noninvasive specimens and their lineage functions preserved during the long-term culture. These CR cells retain their ability to differentiate at air-liquid interface (ALI). Here, we recapitulated the applications of CR and ALI approaches in modeling host-virus interactions and viral-mediated tumorigenesis.
Keywords: EBV; HPV; air–liquid interface; conditional cell reprogramming; oncogenic viruses.
Conflict of interest statement
Several patents for conditional reprogramming technology were awarded to Georgetown University by the United States Patent Office. The license for this technology was given to a Maryland-based start-up company for commercialization. The inventor, X.L., and Georgetown University receive potential royalties and payments from the company. CR media and CR cells were distributed by Propagenix, StemCell Technology, Fisher Scientific, ATCC, etc. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The other authors declare no conflicts of interest. The authors are responsible for the content and writing of this manuscript.
Figures
Similar articles
-
Inhibition of Epstein-Barr Virus Replication in Human Papillomavirus-Immortalized Keratinocytes.J Virol. 2019 Jan 4;93(2):e01216-18. doi: 10.1128/JVI.01216-18. Print 2019 Jan 15. J Virol. 2019. PMID: 30381489 Free PMC article.
-
Conditional cell reprogramming for modeling host-virus interactions and human viral diseases.J Med Virol. 2020 Nov;92(11):2440-2452. doi: 10.1002/jmv.26093. Epub 2020 Jun 16. J Med Virol. 2020. PMID: 32478897 Free PMC article. Review.
-
Conditionally Reprogrammed Human Normal Airway Epithelial Cells at ALI: A Physiological Model for Emerging Viruses.Virol Sin. 2020 Jun;35(3):280-289. doi: 10.1007/s12250-020-00244-z. Epub 2020 Jun 17. Virol Sin. 2020. PMID: 32557270 Free PMC article. Review.
-
The First Human Vulvar Intraepithelial Neoplasia Cell Line with Naturally Infected Episomal HPV18 Genome.Viruses. 2022 Sep 16;14(9):2054. doi: 10.3390/v14092054. Viruses. 2022. PMID: 36146860 Free PMC article.
-
Deciphering the Relationship between SARS-CoV-2 and Cancer.Int J Mol Sci. 2023 Apr 25;24(9):7803. doi: 10.3390/ijms24097803. Int J Mol Sci. 2023. PMID: 37175509 Free PMC article. Review.
Cited by
-
Modeling respiratory tract diseases for clinical translation employing conditionally reprogrammed cells.Cell Insight. 2024 Sep 18;3(6):100201. doi: 10.1016/j.cellin.2024.100201. eCollection 2024 Dec. Cell Insight. 2024. PMID: 39391007 Free PMC article. Review.
-
BRD4 as a potential target for human papillomaviruses associated cancer.J Med Virol. 2023 Dec;95(12):e29294. doi: 10.1002/jmv.29294. J Med Virol. 2023. PMID: 38100650 Free PMC article. Review.
-
Identification of HPV oncogene and host cell differentiation associated cellular heterogeneity in cervical cancer via single-cell transcriptomic analysis.bioRxiv [Preprint]. 2023 Aug 14:2023.08.10.552878. doi: 10.1101/2023.08.10.552878. bioRxiv. 2023. Update in: J Med Virol. 2023 Aug;95(8):e29060. doi: 10.1002/jmv.29060 PMID: 37645794 Free PMC article. Updated. Preprint.
-
Unlocking Translational Potential: Conditionally Reprogrammed Cells in Advancing Breast Cancer Research.Cells. 2023 Sep 30;12(19):2388. doi: 10.3390/cells12192388. Cells. 2023. PMID: 37830602 Free PMC article. Review.
References
-
- Ndubisi B., Sanz S., Lu L., Podczaski E., Benrubi G., Masood S. The prognostic value of HER-2/neu oncogene in cervical cancer. Ann. Clin. Lab. Sci. 1997;27:396–401. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources